Clinical trials: Clostridium Difficile Infection Recurrence
Clostridium Difficile Infection
Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections
Patients with confirmed C. difficile infection (CDI) who meet eligibility requirements will be invited to participate. All study patients must receive treatment for CDI with metronidazole or vancomycin.
- Trial name
- NCT01077245
- Testing
- MIYA-BM Fine Granules (CBM588)
- Sponsor
- Osel, Inc.
Clostridioides Difficile Infection
Clostridioides Difficile: Understanding Responses and Treatment Effects
The goal of this observational study is to learn how different treatments for Clostridioides difficile infection (CDI) work, and which biological mechanisms are involved in recovery.
- Trial name
- CURE-CDI (NCT07374094)
- Testing
- Antibiotic treatment, Fecal microbiota transplantation (FMT)
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Umeå University
Clostridium Difficile Infection
Fecal Microbiota Transplantation for C Diff Infection
The objective of this study is to provide treatment with Fecal Microbiota Transplantation (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI).
- Trial name
- NCT01905709
- Testing
- Human fecal matter
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Englewood Hospital and Medical Center
Clostridium Difficile Colitis
Extended Treatment With Vancomycin for Clostridium Difficile Colitis
BACKGROUND: Clostridium difficile-associated colitis is an infection of the large bowel, usually associated with previous use of antibiotics.
- Trial name
- NCT00861887
- Testing
- Standard Vancomycin, Extended Vancomycin
- Where
- United States
- Sponsor
- Corewell Health East
Clostridium Difficile Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI), and will compare the efficacy of one treatment with RBX2660 versus antibiotic-treated…
- Trial name
- NCT02589847
- Testing
- RBX2660, Standard of Care Antibiotics
- Where
- 30 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Rebiotix Inc.
Clostridioides Difficile Infection Recurrence
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map the risk of having a C.
- Trial name
- NCT07250724
- Testing
- Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bactolife A/S
Clostridium Enterocolitis, Pseudomembranous Colitis
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
The purpose of this study is to compare the outcome of treatment with nitazoxanide vs. vancomycin for diarrheal disease due to Clostridium difficile in patients who have failed previous treatment with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304889
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Infection
A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection
This study is a two-arm, interventional, prospective, open-label, multi-center clinical trial with randomized and non-randomized study groups to evaluate the safety and effectiveness of faecal microbiota transplantation (FMT) for…
- Trial name
- FMTREAT (NCT03053505)
- Testing
- faecal human microbiota transplant (FMT), Vancomycin or Fidaxomicin
- Where
- 3 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Sejtterapia Kozpont Kft.
Clostridium Difficile Infection
PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA
A higher frequency of recurrences in the University Hospital of Cabueñes (HUCAB) than in other hospitals in our area, including Central University Hospital of Asturias (HUCA) has been found.
- Trial name
- NCT04259931
- Testing
- microbiome analysis
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario de Cabuenes
Clostridioides Difficile Infection
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin…
- Trial name
- FENDER (NCT05266807)
- Testing
- oral capsulized Fecal Microbiota Transplantation, Vancomycin or Fidaxomicin
- Where
- 8 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Benoit Guery
Inflammatory Bowel Diseases, Clostridium Difficile Infection
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
This is a randomized controlled trial to assess the clinical and microbiological impacts of FMT in combination with Bezlotoxumab (bezlo) compared to FMT in combination with placebo in patients with both inflammatory bowel disease…
- Trial name
- ICON-2 (NCT03829475)
- Testing
- Bezlotoxumab, Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Brigham and Women's Hospital
Clostridium Difficile Infection
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group II.
- Trial name
- ECOSPORIII (NCT03183128)
- Testing
- SER-109
- Where
- 56 sites in United States, Canada
- Volunteers
- 182 people
- Sponsor
- Seres Therapeutics, Inc.
Clostridia Difficile Colitis, Clostridium Difficile Diarrhea
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
Fecal microbiota transplantation (FMT) is a treatment that restores the balance of gut bacteria and is the most effective treatment for patients who suffer from recurrent Clostridioides difficile infection (CDI) brought on by…
- Trial name
- NCT03806803
- Testing
- Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate
- Where
- 5 sites in Canada
- Volunteers
- 138 people
- Sponsor
- University of Alberta
Clostridium Difficile Infection Recurrence
A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
This is a randomized, placebo-controlled, double-blind, multi-site study in which up to approximately 36 subjects with a recent C.
- Trial name
- NCT04891965
- Testing
- ART24
- Where
- 15 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Adiso Therapeutics
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%).
- Trial name
- FILTRATE (NCT04960306)
- Testing
- Fecal filtrate transplantation, Conventional fecal microbiota transplantation
- Where
- Hungary
- Volunteers
- 238 people
- Sponsor
- University of Pecs
Clostridioides Difficile Infection
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C.
- Trial name
- PREVENT (NCT06884748)
- Testing
- Ursodiol 500 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical…
- Trial name
- NCT04317963
- Testing
- Bezlotoxumab, Standard CDI treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Illinois at Chicago